isotretinoin and Osteosarcoma

Biologic response modifiers are becoming an important addition to surgery, chemotherapy, and radiotherapy in the management of cancer. As this field of research grows and expands, more biologic response modifiers will be incorporated into therapeutic regimens. By stimulating the immune system to eradicate minimal residual disease, these agents may improve the disease-free and long-term survival rates of patients with a variety of malignancies. The challenge is to incorporate biologic response modifiers into the treatment armamentarium in ways that will maximize their tumorigenicity.

Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytokines; Drug Design; Hematopoietic Cell Growth Factors; Humans; Immunologic Factors; Immunotherapy; Infant; Interleukins; Isotretinoin; Liposomes; Neoplasms; Neuroblastoma; Osteosarcoma; Phosphatidylcholines; Phosphatidylethanolamines; Phosphatidylglycerols; Salvage Therapy; Sarcoma, Ewing